BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
- 31 July 2014
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 20 (15) , 4001-4013
Abstract
Purpose: To identify a novel biomarker for bladder cancer targeting therapy. Experimental Design: The human bladder cancer cell line T24 cells were used as immunogen to generate mouse monoclonal antibodies. We screened and identified a specific antibody BCMab1 against bladder cancer. We examined BCMab1 antigen expression in the patients with bladder cancer through immunohistochemical staining and investigated the BCMab1 antigen association with clinical severity. We detected the antitumor activity of BCMab1 antibody and investigated its therapeutic efficacy by subcutaneous and orthotopic bladder cancer models. Results: We developed a new monoclonal antibody BCMab1 against bladder cancer that specifically recognized the aberrantly glycosylated Integrin α3β1 epitope on bladder cancer cells. Expression of the BCMab1 antigen was consistent with clinical severity and prognosis of bladder cancer. The glycosyltransferase GALNT1 could contribute to aberrant glycosylation of Integrin α3. The aberrant glycosylation of integrin α3–activated integrin signaling to initiate FAK activation. BCMab1 could block Integrin engagement to inhibit its signaling leading to cell-cycle arrest. In addition, BCMab1 enhanced FcγR-dependent antitumor activity in vivo. Conclusions: BCMab1 antigen is a new biomarker for bladder cancer. BCMab1 antibody exhibited potent antitumor activity against bladder cancer in vivo. Clin Cancer Res; 20(15); 4001–13. ©2014 AACR.Keywords
All Related Versions
This publication has 41 references indexed in Scilit:
- Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathwaysOncogene, 2012
- Basic amino-acid side chains regulate transmembrane integrin signallingNature, 2011
- Efficient construction of sequence-specific TAL effectors for modulating mammalian transcriptionNature Biotechnology, 2011
- Antibody recognition of a unique tumor-specific glycopeptide antigenProceedings of the National Academy of Sciences, 2010
- Isoform-specific O-Glycosylation of Osteopontin and Bone Sialoprotein by Polypeptide N-Acetylgalactosaminyltransferase-1Journal of Biological Chemistry, 2010
- An integrin αvβ3–c-Src oncogenic unit promotes anchorage-independence and tumor progressionNature Medicine, 2009
- Inactivating germ-line and somatic mutations in polypeptide N -acetylgalactosaminyltransferase 12 in human colon cancersProceedings of the National Academy of Sciences, 2009
- Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signalingJournal of Clinical Investigation, 2009
- Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progressionProceedings of the National Academy of Sciences, 2007
- Fibronectin Rigidity Response through Fyn and p130Cas Recruitment to the Leading EdgeMolecular Biology of the Cell, 2006